Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics falls -24.1%
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX